Compare GSHD & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | TWST |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2018 | 2018 |
| Metric | GSHD | TWST |
|---|---|---|
| Price | $73.26 | $33.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $94.70 | $44.88 |
| AVG Volume (30 Days) | 344.1K | ★ 1.3M |
| Earning Date | 10-22-2025 | 02-02-2026 |
| Dividend Yield | ★ 8.05% | N/A |
| EPS Growth | ★ 68.12 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | $353,231,000.00 | ★ $376,572,000.00 |
| Revenue This Year | $16.92 | $15.19 |
| Revenue Next Year | $19.43 | $15.10 |
| P/E Ratio | $64.65 | ★ N/A |
| Revenue Growth | ★ 25.01 | 20.32 |
| 52 Week Low | $64.41 | $23.30 |
| 52 Week High | $127.99 | $55.33 |
| Indicator | GSHD | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 60.22 |
| Support Level | $70.47 | $30.21 |
| Resistance Level | $79.85 | $33.75 |
| Average True Range (ATR) | 2.61 | 1.79 |
| MACD | -0.27 | 0.17 |
| Stochastic Oscillator | 44.35 | 90.65 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.